Golfyeti,

I prefer your response because it is easier for me to understand and I know Apabetalone is not a statin, but at the end of Bear's technical response he comes around closer to my position on the marketing approach.  What I did not initially make clear was that Apabetalone is not a statin and that I never thought it was.  I was interested in the cocktail approach and marketing.   Seems to be enough money in marketing a new and improved statin formulation (how many billion/year?), all in one pill.  Once it is in one pill, you can call it a statin or and epigentic.  Don was saying at the AGM that the masses do not understand what an epigentic is and that he is getting worn out trying to explain it.  A simpler name for the new pill -  EPIDON    :)   Why isn't he already marketing it this way?

JMHO

Absolutely